

BIO RAD LABORATORIES INC
 Form 4
 September 12, 2016

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2015
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 Magni Giovanni

(Last) (First) (Middle)

C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE

(Street)

HERCULES, CA 94547

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
 BIO RAD LABORATORIES INC [BIO, BIOB]

3. Date of Earliest Transaction (Month/Day/Year)
 09/08/2016

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

____ Director _____ 10% Owner
 Officer (give title below) _____ Other (specify below)
 EVP, Chief Strategy Officer

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 ____ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
				(A) or (D)	Price		
				Code	V	Amount	
Bio-Rad A Common Stock	09/10/2016		M	400 ⁽¹⁾ A	\$ 0	13,055	D
Bio-Rad A Common Stock	09/11/2016		M	740 ⁽¹⁾ A	\$ 0	13,795	D
Bio-Rad A Common Stock	09/12/2016		S	438 ⁽²⁾ D	\$ 155.019 ⁽³⁾	13,357	D

Edgar Filing: BIO RAD LABORATORIES INC - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Security (Instr. 3 and 4)	Amount or Number of Shares
Restricted Stock Units	\$ 0 ⁽⁴⁾	09/08/2016		A	2,000	⁽⁵⁾ ⁽⁵⁾	Bio-Rad A Common Stock	2,000
Non-Qualified Stock Option (right to buy)	\$ 160.37	09/08/2016		A	2,000	⁽⁶⁾ 09/08/2026	Bio-Rad A Common Stock	2,000
Restricted Stock Units	\$ 0 ⁽⁴⁾	09/10/2016		M	400	⁽⁷⁾ ⁽⁷⁾	Bio-Rad A Common Stock	400
Restricted Stock Units	\$ 0 ⁽⁴⁾	09/11/2016		M	240	⁽⁸⁾ ⁽⁸⁾	Bio-Rad A Common Stock	240
Restricted Stock Units	\$ 0 ⁽⁴⁾	09/11/2016		M	500	⁽⁹⁾ ⁽⁹⁾	Bio-Rad A Common Stock	500

Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other
EVP, Chief Strategy Officer

Magni Giovanni
C/O BIO-RAD LABORATORIES, INC.
1000 ALFRED NOBEL DRIVE
HERCULES, CA 94547

Signatures

/s/ Ronald W. Hutton,
Attorney-in-fact

09/12/2016

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
 - ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Shares of Class A common stock acquired on the vesting of restricted stock units.
 - (2) Sold by the Issuer on behalf of the Reporting Person to satisfy certain tax obligations in connection with the vesting of restricted stock units, all in accordance with a restricted stock unit award agreement.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$155.0162 to \$155.0209, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
 - (3) Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
 - (4) Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
 - (5) The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant.
 - (6) The stock option vests over five years at 20% per year on the yearly anniversary date of the grant.
 - (7) The restricted stock units vest in five equal annual installments beginning September 10, 2015.
 - (8) The restricted stock units vest in five equal annual installments beginning September 11, 2014.
 - (9) The restricted stock units vest in five equal annual installments beginning September 11, 2016.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.